Company: CORT
Filing Date: 2025-07-31
Form Type: 10-Q
Source: 0001628280-25-037005
Chunk: 1

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-07-31
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
 June 30,Six Months Ended June 30, 2025202420252024Product revenue, net$194,430 $163,796 $351,644 $310,604 Operating expenses:Cost of sales3,433 2,524 5,836 5,059 Research and development60,471 58,745 121,206 117,251 Selling, general and administrative103,851 66,935 194,511 123,203 Total operating expenses167,755 128,204 321,553 245,513 Income from operations26,675 35,592 30,091 65,091 Interest and other income5,017 6,004 11,219 11,498 Income before income taxes31,692 41,596 41,310 76,589 Income tax benefit (expense)3,457 (6,108)14,386 (13,339)Net income35,149 35,488 55,696 63,250 Net income attributable to common stockholders34,611 35,120 54,918 62,640 Basic net income per common share$0.33 $0.34 $0.53 $0.61 Diluted net income per common share$0.29 $0.32 $0.46 $0.57 Weighted-average shares outstanding used in computing net income per common shareBasic104,111 103,118 104,108 102,954 Diluted120,485 111,244 120,227 110,550 

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

CORCEPT THERAPEUTICS INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)

(In thousands)Three Months Ended June 30,Six Months Ended June 30, 2025202420252024Net income35,149 35,488 55,696 63,250 Other comprehensive income (loss):Unrealized gain (loss) on available-for-sale investments, net of tax effect of $21, $14, $(154) and $117, respectively163 (189)714 (519)Foreign currency translation gain (loss)1,436 15 1,794 (6)Total